FLEXTRADE-SYSTEMS
24.5.2023 09:31:31 CEST | Business Wire | Press release
FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems, has announced the launch of artificial intelligence-driven (AI) functionality within its flagship multi-asset solution, FlexTRADER EMS. The new interface layer is designed to revolutionize how trading teams interact with their data and trading technology solutions.
Over the past year, OpenAI driven-solutions such as ChatGPT and its latest version, GPT-4, which apply natural language processing to large language model (LLM) systems, have been in the spotlight, with firms racing to understand their uses for the trading space. However, the new offering from FlexTrade is one of the first practical examples of the technology being used directly within an OEMS solution.
The groundbreaking innovation, which has the working name of FlexA, is a voice-activated application developed by FlexTrade's in-house data science team as part of its ongoing R&D function and commitment to delivering innovation to its customer base. The solution provides an AI layer across FlexTRADER EMS to simplify the interaction between the trader and their trading technology platform and easily and intuitively work with vast swathes of information outside the more traditional 2D grid visualization and input devices currently used.
With the new solution, traders using FlexTRADER EMS, with FlexA enabled, can apply natural language to interrogate and control the solution via voice commands or a text-based chat interface in several ways. For instance, clients can ask verbal or written questions to quickly and easily achieve a deep situational awareness of orders within their blotter using a combination of specific criteria or characteristics such as "What is the value of my Swiss orders over 10% ADV?". Additionally, traders can request ad-hoc reports on historical trading with specific visualization formats, including tables and charts, to assist with pre-trade decision-making. For example: "Show me a chart of my traded venues for US orders in Feb." Furthermore, traders can send actions to be automated to help speed up workflow. For instance, "create a ticket for my US orders less than 500k using the VWAP AlgoWheel" or "merge AAPL."
Vijay Kedia, CEO, FlexTrade Systems Inc., stated: "The introduction of OpenAI and ChatGPT is a revolutionary moment in consumer technology, and the speed at which we've incorporated it across FlexTRADER EMS is a milestone achievement. It enables traders to use natural language to rapidly interact, interrogate and understand data in the manner which makes the most sense to them. The outcome is that it erodes the barriers created by traditional input devices such as keyboard and mouse, enabling trading teams to work quickly to understand and optimize their pre-trade decisions, which is paramount in a constantly changing environment."
Vikas Kedia, Managing Director of Strategic Initiatives & Emerging Solutions at FlexTrade, commented: "FlexTrade's R&D and innovation teams continuously and proactively evaluate the latest technologies, as they become available, to understand the practical applications to buy-and-sell-side trading desks. From machine learning and our sophisticated real-time market impact analytics offering to, most recently, AI, we are working with our client base and business users to refine and explore further applications across global trading desks. It's an approach that ensures our clients stay at the forefront of cutting-edge developments in trading technology."
About FlexTrade Systems:
FlexTrade Systems is a global leader in high-performance multi-asset execution management and order management systems for equities, fixed income, foreign exchange, futures, and options. A pioneer in the field, FlexTrade is internationally recognized for introducing FlexTRADER®, the world's first broker-neutral execution management trading system. It allows clients to completely control and customize their execution workflows through a comprehensive ability to search/access liquidity while maintaining the confidentiality of their trading strategies.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005117/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Circularity Data: Nine Out of Ten Returned Items Lose Value for Retailers10.9.2026 13:33:00 CEST | Press release
New research finds 86% of retailers have established circularity practices, yet only 9% resell more than half of returned products at full price New research from ReBound Returns and Advanced Supply Chain (ASC) has revealed a gap between retailers’ circularity ambitions and the value they are recovering from returned products. The Circularity Index, based on research among 150 senior leaders at mid-to-large UK and European retailers, found that 86% have an established approach to circularity in returns, with practices including resale, refurbishment, repair and recycling regularly used across the business. For 27%, circularity is a core part of how returns are managed. However, translating those strategies into commercial value remains difficult. On average, 12% of returned items generate no value, while only 9% of retailers resell more than half of their returned products at full price. There is also a significant opportunity still to be captured. 82% of retailers believe that up to h
One Biosciences Receives €3,3 Million Funding Under i-Démo 5 From France 2030 to Accelerate Development of First Single-Cell Diagnostic for Triple-Negative Breast Cancer, in Collaboration With Institut Curie10.9.2026 13:02:00 CEST | Press release
One Biosciences, a techbio company spun off from Institut Curie pioneering clinical-grade single-cell tumor profiling, and Institut Curie, the leading French center for the fight against cancer, today announced support from Bpifrance through the France 2030 i-Démo1 program for the CAST project (Cancer Single-cell Analysis for Therapy), securing €3,3 Million in funding. This milestone marks a major step forward in the development of single-cell tumor profiling technology for routine cancer care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910763012/en/ Triple-negative breast cancer (TNBC) represents approximately 15–20% of breast cancer cases. Patients face high relapse rates, rapid disease progression and limited treatment options, while clinicians still lack reliable biomarkers to predict which patients will respond to immunotherapy or chemotherapy combinations. Current diagnostic approaches average signals across mil
New WSJ Intelligence Survey Highlights the Human Skills Companies Must Protect as AI Enters the Workplace10.9.2026 13:00:00 CEST | Press release
The Cognition Index Research Report, launched in partnership with Philip Morris International, warns of “Cognitive Atrophy” and a growing AI trust gap in the workplace Philip Morris International (PMI) (NYSE: PM) and WSJ Intelligence, the in-house thought leadership consultancy for The Wall Street Journal's commercial sales organization, today unveiled The Cognition Index Research Report, a comprehensive study exploring the evolving role of human cognition in an AI-driven workplace. Surveying more than 2,500 business professionals across the United States, United Kingdom, Italy, South Africa, and Brazil, the report reveals that while business professionals are increasingly optimistic about AI’s role in improving decision-making, they continue to see human judgment, ethics, critical thinking and empathy as essential capabilities that must be actively protected and developed as AI becomes embedded in workplace workflows. “Human cognition is a bit like a muscle: use it or lose it,” says M
Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training10.9.2026 12:35:00 CEST | Press release
Five organizations awarded grants, above the planned three, as a result of a competitive selection process with highly qualified applicants Training guidance is designed to prepare healthcare providers to deliver high-quality treatment experiences to patients receiving COMP360, if approved Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today the U.S. grant program recipients to create training programs for healthcare providers (HCPs) that will be involved in the delivery of psychedelic treatments, such as COMP360 psilocybin. These programs are intended to address both the need for foundational training in psychedelics, as well as ensuring HCPs are well-prepared to care for patients receiving treatment with COMP360 following its expected commercial launch, if approved. The recipients were selected through a competitive application process based on their expertise and proven abilit
Compass Pathways to Participate in Investor Conferences the Week of September 14th10.9.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will participate in the following investor conferences the week of September 14th: H.C. Wainwright Annual Global Investment Conference – New York, NY: Fireside chat at 3:30pm ET on September 15, 2026 Morgan Stanley 24th Annual Global Healthcare Conference – New York, NY: Fireside chat at 11:30am ET on September 16, 2026 Deutsche Bank’s 2026 Healthcare Summit – New York, NY: Fireside chat at 11:00am ET on September 17, 2026 A live audio webcast of the fireside chats will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlockin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
